Literature DB >> 27469281

Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism.

Janice C Froehlich1, Stephen M Fischer2, Julian E Dilley1, Emily R Nicholson1, Teal N Smith1, Nick J Filosa1, Logan C Rademacher1.   

Abstract

BACKGROUND: This study examined whether varenicline (VAR), or naltrexone (NTX), alone or in combination, reduces alcohol drinking in alcohol-preferring (P) rats with a genetic predisposition toward high voluntary alcohol intake.
METHODS: Alcohol-experienced P rats that had been drinking alcohol (15% v/v) for 2 h/d for 4 weeks were fed either vehicle (VEH), VAR alone (0.5, 1.0, or 2.0 mg/kg body weight [BW]), NTX alone (10.0, 15.0, or 20.0 mg/kg BW), or VAR + NTX in 1 of 4 dose combinations (0.5 VAR + 10.0 NTX, 0.5 VAR + 15.0 NTX, 1.0 VAR + 10.0 NTX, or 1.0 VAR + 15.0 NTX) at 1 hour prior to alcohol access for 10 consecutive days, and the effects on alcohol intake were assessed.
RESULTS: When administered alone, VAR in doses of 0.5 or 1.0 mg/kg BW did not alter alcohol intake but a dose of 2.0 mg/kg BW decreased alcohol intake. This effect disappeared when drug treatment was terminated. NTX in doses of 10.0 and 15.0 mg/kg BW did not alter alcohol intake but a dose of 20.0 mg/kg BW decreased alcohol intake. Combining low doses of VAR and NTX into a single medication reduced alcohol intake as well as did high doses of each drug alone. Reduced alcohol intake occurred immediately after onset of treatment with the combined medication and continued throughout prolonged treatment.
CONCLUSIONS: Low doses of VAR and NTX, when combined in a single medication, reduce alcohol intake in a rodent model of alcoholism. This approach has the advantage of reducing potential side effects associated with each drug. Lowering the dose of NTX and VAR in a combined treatment approach that maintains efficacy while reducing the incidence of negative side effects may increase patient compliance and improve clinical outcomes for alcoholics and heavy drinkers who want to reduce their alcohol intake.
Copyright © 2016 by the Research Society on Alcoholism.

Entities:  

Keywords:  Alcohol Drinking; Alcohol Treatment; Naltrexone; Selectively Bred Rats; Varenicline

Mesh:

Substances:

Year:  2016        PMID: 27469281      PMCID: PMC5297249          DOI: 10.1111/acer.13157

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  56 in total

1.  Importance of delta opioid receptors in maintaining high alcohol drinking.

Authors:  J C Froehlich; M Zweifel; J Harts; L Lumeng; T K Li
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Prazosin Reduces Alcohol Intake in an Animal Model of Alcohol Relapse.

Authors:  Janice C Froehlich; Brett Hausauer; Stephen Fischer; Bradley Wise; Dennis D Rasmussen
Journal:  Alcohol Clin Exp Res       Date:  2015-08       Impact factor: 3.455

3.  Estimation of area under the curve for drugs subject to enterohepatic cycling.

Authors:  T A Shepard; R H Reuning; L J Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1985-12

4.  Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.

Authors:  Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben
Journal:  JAMA       Date:  2006-05-03       Impact factor: 56.272

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

6.  Adverse effects of oral naltrexone: analysis of data from two clinical trials.

Authors:  C Oncken; J Van Kirk; H R Kranzler
Journal:  Psychopharmacology (Berl)       Date:  2001-04       Impact factor: 4.530

7.  Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence.

Authors:  A C King; J R Volpicelli; A Frazer; C P O'Brien
Journal:  Psychopharmacology (Berl)       Date:  1997-01       Impact factor: 4.530

8.  Disulfiram treatment of alcoholism. A Veterans Administration cooperative study.

Authors:  R K Fuller; L Branchey; D R Brightwell; R M Derman; C D Emrick; F L Iber; K E James; R B Lacoursiere; K K Lee; I Lowenstam
Journal:  JAMA       Date:  1986-09-19       Impact factor: 56.272

9.  Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.

Authors:  Lara A Ray; Kelly E Courtney; Dara G Ghahremani; Karen Miotto; Arthur Brody; Edythe D London
Journal:  Psychopharmacology (Berl)       Date:  2014-04-15       Impact factor: 4.530

Review 10.  Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis.

Authors:  Kyla H Thomas; Richard M Martin; Duleeka W Knipe; Julian P T Higgins; David Gunnell
Journal:  BMJ       Date:  2015-03-12
View more
  9 in total

1.  Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats.

Authors:  Janice C Froehlich; Emily R Nicholson; Julian E Dilley; Nick J Filosa; Logan C Rademacher; Teal N Smith
Journal:  Alcohol Clin Exp Res       Date:  2017-07-10       Impact factor: 3.455

2.  The Effects of Long-Term Varenicline Administration on Ethanol and Sucrose Seeking and Self-Administration in Male P Rats.

Authors:  Cristine L Czachowski; Janice C Froehlich; Michael DeLory
Journal:  Alcohol Clin Exp Res       Date:  2017-12-23       Impact factor: 3.455

Review 3.  Prevention, screening, and treatment for heavy drinking and alcohol use disorder.

Authors:  Justin Knox; Deborah S Hasin; Farren R R Larson; Henry R Kranzler
Journal:  Lancet Psychiatry       Date:  2019-10-17       Impact factor: 27.083

4.  Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats.

Authors:  Emily R Nicholson; Julian E Dilley; Janice C Froehlich
Journal:  Alcohol Clin Exp Res       Date:  2018-01-22       Impact factor: 3.455

5.  Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats.

Authors:  Robert A Waeiss; Christopher P Knight; Sheketha R Hauser; Lauren A Pratt; William J McBride; Zachary A Rodd
Journal:  Psychopharmacology (Berl)       Date:  2019-02-13       Impact factor: 4.530

6.  A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking.

Authors:  Janice C Froehlich; Stephen M Fischer; Emily R Nicholson; Julian E Dilley; Nicholas J Filosa; Teal N Smith; Logan C Rademacher
Journal:  Alcohol Clin Exp Res       Date:  2017-02-09       Impact factor: 3.455

7.  Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.

Authors:  Yan Zhou; Francesco Leri; Malcolm J Low; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2019-04-13       Impact factor: 3.533

Review 8.  Medications for alcohol use disorders: An overview.

Authors:  Mohammed Akbar; Mark Egli; Young-Eun Cho; Byoung-Joon Song; Antonio Noronha
Journal:  Pharmacol Ther       Date:  2017-12-02       Impact factor: 12.310

Review 9.  Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.

Authors:  Elizabeth M Burnette; Steven J Nieto; Erica N Grodin; Lindsay R Meredith; Brian Hurley; Karen Miotto; Artha J Gillis; Lara A Ray
Journal:  Drugs       Date:  2022-02-08       Impact factor: 9.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.